In Praise of Non-Inferiority
Dear All (wonkish but intended for everybody to read and absorb): 27 Jan 2021 update: This topic now has its own YouTube video! As the
19 September 2020
No Comments
R&D Insight
The language of AMR: The power of metaphor
Dear All, Acronyms and jargon fill our daily scientific lives but can be impenetrable to newcomers. A great example is the title of the 20 Feb
7 April 2026
No Comments
Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery
Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call is that the resistance arises
19 April 2026
No Comments
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct is due to Patricia and
16 April 2026
No Comments
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating
12 March 2026
No Comments
AMR Surveillance Data Challenge – Vivli 2026 Call for Projects!
Dear All, I’ve written before about the Vivli data challenge (2024 edition, 2025 edition) and am pleased to be able to say that there is
14 April 2026
No Comments
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Note: See also these related newsletters: 20 Feb 2020 (link) on DTR as part of the language of resistance and 7 June 2020 (link) on
13 January 2019
No Comments
GO-Dx: Global One Health Diagnostics Access Compact
Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, it really has been 10
9 April 2026
No Comments
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for co-authoring this newsletter), In a
1 March 2026
No Comments
CARB-X seeks new Chief of R&D (fully remote, worldwide)
Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research & Development! Given CARB-X’s role as
9 March 2026
No Comments